FDA reviews Eli Lilly's lung cancer drug necitumumab; Catabasis gets fast track for DMD drug;

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Aimmune joins the biotech IPO scrum in search of $115M--plus a roundup of biotech IPO news. More | Follow @JohnCFierce

@DamianFierce: $AGN is paying $MRK $250M to become the roughly 127th company developing CGRP blockers for migraine. Release | Follow @DamianFierce

> The FDA issued its internal review of Eli Lilly's cancer drug necitumumab today, noting some serious safety issues and a marginal gain in survival rates. The review includes a review of two studies for the drug, one of which was stopped due to safety factors. Eli Lilly ($LLY) has submitted data from a separate study that concludes patients taking the drug along with a chemo combo gained a 1.6-month advantage in terms of overall survival rates. External FDA experts will vote on the drug--designed for non-small cell lung cancer--following a panel discussion on Thursday. Reuters reports that  analysts expect the drug can deliver $582 million in annual sales by 2020, if it's approved. Story

> Cambridge, MA-based Catabasis says that CAT-1004 has received Fast Track designation from the FDA for the treatment of Duchenne muscular dystrophy. Release

Medical Device News

@FierceMedDev: Natera bags $180M in IPO to ramp up R&D. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: FDA warns that Maquet's anesthesia system could lead to a fatal stop in ventilation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: BG Medicine gets FDA blessing for automated chronic heart failure test. Article | Follow @EmilyWFierce

> DEKA gets $7M from DARPA to develop prosthetic arm with a sense of touch. News

> Report: Repeal of medical device tax gaining traction in Congress. More

Pharma News

@FiercePharma: Horizon targets Depomed's pain portfolio with $3B hostile bid. News | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Report | Follow @CarlyHFierce

> AstraZeneca and Cephalon pony up $50M+ to settle Medicaid pricing claims. News

> Doctor faces sentencing for 'over the top' cancer drug dosing. Item

> Mylan didn't disclose director's ties to HQ land deal: WSJ. Report

Drug Delivery News

> Natural bioluminescence provides inside look at drug-cell interactions. Story

> FDA to review modified-release version of Pfizer's Xeljanz for rheumatoid arthritis. More

> Novo ends microneedle patch diabetes partnership with Zosano. Article

> UCSB team tackles aggressive kidney disease by hitching a ride into cysts. Story

> China's Wuzhou says it will take 10% stake in oral insulin specialist Oramed for $52M. Report

Pharma Manufacturing News

> India's Lupin gets Russian production site in deal for Biocom. More

> Boehringer Ingelheim unloads vet plant in Iowa to contract manufacturer. Story

> FDA warns consumers to check any generic Valium bought online; it may be dangerous. Article

> Actavis yanks more than half a million boxes of birth control pills for packaging faux pas. News

> Europe says Israel and Brazil can ship APIs without having to certify them. Item

Pharma Asia News

> China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus. More

> Shanghai, Shenzhen IPO halts won't spoil the China healthcare party. Story

> More trouble for India's CROs as Quest Life Sciences hauled up by WHO in HIV trial. Report

> Indian court upholds BMS Sprycel patent, but list of challengers grows. News

> Alibaba Health plans wider online sales push in China as competition heats up. Article

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.